Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy

Kidney International

Volumn 80, Issue 3, 2011, Pages 272-281

  Fugmann, Tim ^a   Borgia, Beatrice ^a   Révész, Csaba ^b   Godó, Mária ^b   Forsblom, Carol ^c,d   Hamar, Peter ^b   Holthöfer, Harry ^e   Neri, Dario ^a   Roesli, Christoph ^a  

^a ETH ZURICH   (Switzerland)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

diabetic nephropathy; diagnosis; podocyte; vascular access

Indexed keywords

4F2 CELL SURFACE ANTIGEN HEAVY CHAIN; ALPHA ACTININ 4; BIOTIN; CD151 ANTIGEN; COLLAGEN TYPE 4; COLLAGEN TYPE 4 ALPHA 3; DECORIN; ENG PROTEIN; ENPP6 PROTEIN; ENZYME; ESTER DERIVATIVE; GLUTATHIONE PEROXIDASE 1; HAPTOGLOBIN; INTERCELLULAR ADHESION MOLECULE 2; KIN OF IRRE LIKE PROTEIN 1; KININOGEN; KININOGEN I; MEMBRANE ANTIGEN; MEMBRANE METALLOENDOPEPTIDASE; NEUROPILIN 1; OROSOMUCOID; PODOCALYXIN; PROTEIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE D30; SOLUTE CARRIER FAMILY 22 MEMBER 2; STREPTOZOCIN; TAMM HORSFALL GLYCOPROTEIN; UNCLASSIFIED DRUG; VANIN 1;

ALBUMINURIA; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE MARKER; DISEASE MODEL; DOWN REGULATION; HUMAN; IMMUNOFLUORESCENCE TEST; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY HOMOGENATE; KIDNEY PERFUSION; MACROALBUMINURIA; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; STREPTOZOCIN DIABETES; UPREGULATION; URINALYSIS; WESTERN BLOTTING;

EID: 79960404942     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.116     Document Type: Article

References (56)

1. Daneman D. Type 1 diabetes. Lancet 2006; 367: 847-858. (Pubitemid 43363372)
2. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ 2004; 328: 750-754. (Pubitemid 38406430)
3. Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000; 97: 7667-7669. (Pubitemid 30460701)
4. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Seminars in Nephrology 2007; 27: 195-207. (Pubitemid 46550314)
5. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001; 109(Suppl 2): S424-S437. (Pubitemid 32577594)
6. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-380. (Pubitemid 12188669)
7. Chang SS. Albuminuria and diabetic nephropathy. Pediatr Endocrinol Rev 2008; 5(Suppl 4): 974-979.
8. Crawford PW, Lerma EV. Treatment options for end stage renal disease. Prim Care 2008; 35: 407-432, v.
9. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 1999; 34: 973-995.
10. Steinke JM, Sinaiko AR, Kramer MS et al. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005; 54: 2164-2171. (Pubitemid 40911280)
11. Caramori ML, Kim Y, Huang C et al. Cellular basis of diabetic nephropathy: Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 2002; 51: 1294. (Pubitemid 34438384)
12. Cooper ME, Allen TJ, Macmillan P et al. Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat. Am J Hypertens 1988; 1: 5-10.
13. Epstein PN, Overbeek PA, Means AR. Calmodulin-induced early-onset diabetes in transgenic mice. Cell 1989; 58: 1067-1073. (Pubitemid 19238184)
14. Sharma K, Lee S, Han S et al. Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 2005; 5: 2648-2655. (Pubitemid 40966492)
15. Cho WC, Yip TT, Chung WS et al. Differential expression of proteins in kidney, eye, aorta, and serum of diabetic and non-diabetic rats. J Cell Biochem 2006; 99: 256-268. (Pubitemid 44297969)
16. Thongboonkerd V, Barati MT, McLeish KR et al. Alterations in the renal elastin-elastase system in type 1 diabetic nephropathy identified by proteomic analysis. J Am Soc Nephrol 2004; 15: 650-662. (Pubitemid 38294795)
17. Sitek B, Potthoff S, Schulenborg T et al. Novel approaches to analyse glomerular proteins from smallest scale murine and human samples using DIGE saturation labelling. Proteomics 2006; 6: 4337-4345. (Pubitemid 44277035)
18. Schordan S, Schordan E, Endlich N et al. Alterations of the podocyte proteome in response to high glucose concentrations. Proteomics 2009; 9: 4519-4528.
19. Borgia B, Roesli C, Fugmann T et al. A proteomic approach for the identification of vascular markers of liver metastasis. Cancer Res 2009.
20. Rybak JN, Ettorre A, Kaissling B et al. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods 2005; 2: 291-298. (Pubitemid 41131011)
21. Rybak JN, Roesli C, Kaspar M et al. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res 2007; 67: 10948-10957. (Pubitemid 350145924)
22. Schliemann C, Roesli C, Kamada H et al. In vivo biotinylation of the vasculature in B cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood 2009; 115: 736-744.
23. Castronovo V, Waltregny D, Kischel P et al. A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 2006; 5: 2083-2091. (Pubitemid 44817020)
24. Conrotto P, Roesli C, Rybak J et al. Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer 2008; 123: 2856-2864.
25. Villa A, Trachsel E, Kaspar M et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008; 122: 2405-2413. (Pubitemid 351590471)
26. Roesli C, Neri D, Rybak JN. In vivo protein biotinylation and sample preparation for the proteomic identification of organ-and diseasespecific antigens accessible from the vasculature. Nat Protoc 2006; 1: 192-199.
27. Roesli C, Elia G, Neri D. Two-dimensional mass spectrometric mapping. Curr Opin Chem Biol 2006; 10: 35-41. (Pubitemid 43202285)
28. Scheurer SB, Rybak JN, Roesli C et al. Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics 2005; 5: 2718-2728. (Pubitemid 41059751)
29. Fugmann T, Neri D, Roesli C. DeepQuanTR: MALDI-MS-based label-free quantification of proteins in complex biological samples. Proteomics 2010; 10: 2631-2643.
30. Rudnicki M, Eder S, Perco P et al. Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. Kidney Int 2007; 71: 325-335. (Pubitemid 46227092)
31. Schmid H, Boucherot A, Yasuda Y et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006; 55: 2993-3003. (Pubitemid 44923635)
32. Cadaval RA, Kohlman O, Michelacci YM. Urinary excretion of glycosaminoglycans and albumin in experimental diabetes mellitus. Glycobiology 2000; 10: 185-192. (Pubitemid 30193019)
33. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15: 44-54. (Pubitemid 32203891)
34. Dincer A, Onal S, Timur S et al. Differentially displayed proteins as a tool for the development of type 2 diabetes. Ann Clin Biochem 2009; 46: 306-310.
35. Vionnet N, Tregouet D, Kazeem G et al. Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene. Diabetes 2006; 55: 3166-3174. (Pubitemid 44923657)
36. Roisin-Bouffay C, Castellano R, Valero R et al. Mouse vanin-1 is cytoprotective for islet beta cells and regulates the development of type 1 diabetes. Diabetologia 2008; 51: 1192-1201.
37. Jiang H, Guan G, Zhang R et al. Increased urinary excretion of orosomucoid is a risk predictor of diabetic nephropathy. Nephrology (Carlton) 2009; 14: 332-337.
38. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA 2004; 101: 13368-13373. (Pubitemid 39209672)
39. Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int 2010; 78: 486-494.
40. Chakraborty J, Below AA, Solaiman D. Tamm-Horsfall protein in patients with kidney damage and diabetes. Urol Res 2004; 32: 79-83. (Pubitemid 38915394)
41. Wiggins RC. Uromucoid (Tamm-Horsfall glycoprotein) forms different polymeric arrangements on a filter surface under different physicochemical conditions. Clin Chim Acta 1987; 162: 329-340. (Pubitemid 17050076)
42. Agardh CD, Stenram U, Torffvit O et al. Effects of inhibition of glycation and oxidative stress on the development of diabetic nephropathy in rats. J Diabetes Complications 2002; 16: 395-400. (Pubitemid 35449085)
43. Hong CY, Chia KS. Markers of diabetic nephropathy. J Diabetes Complications 1998; 12: 43-60. (Pubitemid 28028762)
44. Berruyer C, Pouyet L, Millet V et al. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J Exp Med 2006; 203: 2817-2827. (Pubitemid 46026160)
45. Karpuj MV, Becher MW, Springer JE et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002; 8: 143-149. (Pubitemid 34155125)
46. Lee BW, Ihm SH, Choi MG et al. The comparison of cystatin C and creatinine as an accurate serum marker in the prediction of type 2 diabetic nephropathy. Diabetes Res Clin Pract 2007; 78: 428-434.
47. Rakieten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1963; 29: 91-98.
48. Borgia B, Roesli C, Fugmann T et al. A proteomic approach for the identification of vascular markers of liver metastasis. Cancer Res 2010; 70: 309-318.
49. Thorn LM, Forsblom C, Fagerudd J et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005; 28: 2019-2024. (Pubitemid 41060978)
50. Woodfin A, Voisin MB, Nourshargh S. PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol 2007; 27: 2514-2523. (Pubitemid 350158900)
51. Pellet-Many C, Frankel P, Jia H et al. Neuropilins: structure, function and role in disease. Biochem J 2008; 411: 211-226. (Pubitemid 351580173)
52. Wong KS, Proulx K, Rost MS et al. Identification of vasculature-specific genes by microarray analysis of Etsrp/Etv2 overexpressing zebrafish embryos. Dev Dyn 2009; 238: 1836-1850.
53. Aaltonen P, Holthofer H. The nephrin-based slit diaphragm: new insight into the signalling platform identifies targets for therapy. Nephrol Dial Transplant 2007; 22: 3408-3410. (Pubitemid 350212483)
54. Karamatic Crew V, Burton N, Kagan A et al. CD151, the first member of the tetraspanin (TM4) superfamily detected on erythrocytes, is essential for the correct assembly of human basement membranes in kidney and skin. Blood 2004; 104: 2217-2223. (Pubitemid 39331816)
55. Li JJ, Kwak SJ, Jung DS et al. Podocyte biology in diabetic nephropathy. Kidney Int Suppl 2007; 106: S36-S42. (Pubitemid 47172559)
56. Raciti D, Reggiani L, Geffers L et al. Organization of the pronephric kidney revealed by large-scale gene expression mapping. Genome Biol 2008; 9: R84.